华熙生物2024年营收53.71亿元 皮肤类医疗收入超10亿同比增长43.57% 《科创板日报》10日讯，华熙生物（688363.SH）发布2024年度报告显示，公司2024年营收53.71亿元， 原料业务收入12.36亿元，同比增长9.47%；医疗终端业务营收14.40亿元，同比增长32.03%，其中皮肤 类医疗收入10.73亿元，同比大增43.57% ，医美业务变革效果显著，运营能力稳步提升。皮肤科学创新 转化业务营收25.69亿元，未来将从基础生物学前沿研究出发，聚焦糖生物学和细胞生物学，将科研创 新转化为消费品级别的解决方案。当下华熙生物正处于转型关键期，通过逐步解决多项关键运营管理问 题，重回创业型组织，为公司未来实现高质量可持续发展奠定坚实基础。 ...

Core Viewpoint - The A-share market is experiencing a rebound, with significant inflows into the consumer sector, particularly the Consumption ETF (159928), which has seen a notable increase in trading volume and net subscriptions [1][3]. Group 1: Market Performance - The Consumption ETF (159928) rose by 0.96% during trading, with a transaction volume exceeding 630 million yuan and a net subscription of 236 million units [1][3]. - Over the past five days, the ETF has attracted over 160 million yuan in net inflows, and in the last 60 days, it has accumulated nearly 1.3 billion yuan [1][3]. Group 2: Company Highlights - Major stocks within the Consumption ETF have shown positive performance, with North China Grain increasing by the daily limit for three consecutive days, and other companies like Haida Group and Huaxi Biological also seeing significant gains [3]. - Muyuan Foods announced an expected net profit of 4.5 to 5 billion yuan for Q1 2025, a significant turnaround from a loss of 245.9 million yuan in the same period last year, attributed to increased pig sales and lower costs [3]. Group 3: Industry Insights - The food and beverage sector is seen as a rigid support for domestic demand, with a consensus on the necessity to stimulate domestic consumption amid U.S. tariff impacts [3][4]. - Historical data from the 2018 trade friction indicates that the food and beverage sector demonstrated defensive characteristics, with lower declines compared to other sectors during market downturns [4]. - The current valuation of the food and beverage industry is approximately 22 times earnings, which is at a historical low compared to an average of 32 times in 2018 [4][6]. Group 4: Investment Strategy - Recommended investment strategies include focusing on companies with strong fundamentals and growth potential, stable companies with high dividend yields, and sectors with profit elasticity such as the restaurant supply chain [5]. - The top ten stocks in the Consumption ETF account for 67% of the index, with leading positions held by major liquor brands and pig farming companies [8].

Group 1 - The A-share market rebounded today, with the Shanghai Composite Index rising by 0.65%, driven by strong performance in domestic consumption stocks, particularly Beidahuang, which increased by over 9% [1][3] - The Consumption ETF (159928) saw a 1.13% increase during trading, with a transaction volume exceeding 230 million yuan, and a net inflow of over 10 million yuan in the last five days [1][3] - The majority of the index components of the Consumption ETF showed positive performance, with notable gains from stocks such as Bairun Co. and Qiaqia Food, both rising over 4%, and several others like COFCO Sugar and Beitaini increasing by over 3% [3] Group 2 - Central Huijin announced its continued support for the Chinese capital market, emphasizing the value of current A-share investments and its plans to increase holdings in ETFs to maintain market stability [3][4] - Kweichow Moutai has initiated a new share repurchase plan, having repurchased 1.3159 million shares, accounting for 0.1048% of its total share capital, with a total expenditure of 1.948 billion yuan [3] - The company plans to repurchase between 3 billion to 6 billion yuan worth of shares, aimed at reducing registered capital, with the completion of the remaining repurchase expected soon [3] Group 3 - The Consumption ETF has attracted nearly 1.2 billion yuan in the last 60 days, bringing its total scale to over 14.3 billion yuan, a historical high [4] - Citic Securities highlighted the importance of expanding domestic demand and boosting consumption in light of escalating tariff risks, particularly focusing on the food and beverage sector as a key area for investment [4][5] - The report outlines four key sectors to watch: 1) Baijiu (liquor), with Moutai showing stable performance; 2) Low-alcohol beverages, with beer sales rebounding; 3) Restaurant chains benefiting from improved cost margins; 4) Snack foods maintaining high demand due to new products and channels [4][5] Group 4 - The Consumption ETF's index is characterized by its resilience through economic cycles, with the top ten constituent stocks accounting for 67% of the index, including five leading liquor stocks making up 36% [7] - The index's latest price-to-earnings ratio stands at 20.44, which is in the 1.38% percentile of the past ten years, indicating it is cheaper than 98% of the time in the last decade [5]

Core Viewpoint - Aimeike, once celebrated as "the Moutai for women," is facing its most disappointing financial report since its IPO in 2024, with both revenue and net profit growth dropping to around 5%, marking the lowest record since its listing [1][3]. Financial Performance - In 2024, Aimeike reported revenue of 3.026 billion yuan, a year-on-year increase of 5.45%, and a net profit of 1.958 billion yuan, also up by 5.33% [3][9]. - The fourth quarter of 2024 saw a decline in both revenue and net profit, with revenue down 7.0% and net profit down 15.47% year-on-year, attributed to external environment and intensified industry competition [3][4]. - The core product "Haitai," which had previously driven significant revenue, saw a revenue increase of only 4.40% in 2024, compared to a 29.22% increase in 2023 [3][4]. Dividend Policy - Aimeike announced a cash dividend of 38 yuan per 10 shares, totaling approximately 1.145 billion yuan, which represents 58.51% of the company's net profit for 2024, the highest dividend payout since its IPO [9][11]. - Despite the slowdown in revenue growth, the increase in dividend payout indicates a preference for short-term shareholder returns, raising concerns about the adequacy of R&D investment [9][10]. R&D Investment - Aimeike's R&D investment for 2024 was 304 million yuan, accounting for 10.04% of revenue, which is relatively low compared to international peers like Allergan Aesthetics, which maintains a R&D expense ratio above 15% [10][11]. - The company has faced criticism for its limited R&D investment, which has historically remained below 10% of revenue, despite the growing emphasis on technological innovation in the domestic medical aesthetics sector [9][10]. Strategic Acquisition - Aimeike announced the acquisition of 85% of South Korean company REGEN Biotech for 1.9 billion USD (approximately 13.86 billion yuan), marking the largest cross-border acquisition in the domestic medical aesthetics industry [12][13]. - The acquisition aims to enhance Aimeike's product offerings, particularly in the regenerative injection market, but has raised concerns among investors regarding the high premium paid for REGEN [12][13]. - The core product of REGEN, known as "AestheFill" or "童颜针," has been in the market for over a decade, leading to skepticism about its growth potential in a competitive landscape [12][13][15].

Core Viewpoint - The article discusses the internal turmoil and strategic challenges faced by Huaxi Biological, particularly in light of its declining performance and the need for significant internal reforms to address corruption and strategic misalignment [3][4][5]. Group 1: Internal Challenges and Strategic Issues - Huaxi Biological's CEO Zhao Yan issued an ultimatum for employees involved in corruption to resign by March 31, indicating a critical need for internal restructuring [3]. - The company is experiencing a significant decline in revenue and profits, with a reported drop of over 70% in profits for 2024, highlighting the urgency of the situation [3][4]. - The internal issues are compounded by strategic missteps, particularly the failure to adapt to market changes and the overproduction of hyaluronic acid, leading to an oversupply situation [9][15]. Group 2: Market Dynamics and Competitive Landscape - The hyaluronic acid market has shifted from a scarcity to an oversupply, with average prices dropping from 210 RMB per gram in 2017 to 124 RMB in 2021, a decline of 41% [9]. - New competitors in the collagen market have emerged, capturing consumer interest and market share, which has further pressured Huaxi Biological's traditional hyaluronic acid business [11][12]. - The company has been slow to diversify into collagen products, missing out on a significant market opportunity that could have alleviated current pressures [12][15]. Group 3: Financial Performance and Cost Management - Huaxi Biological's sales and management expenses have surged from 38.23% in 2018 to 61.72% in 2023, with sales expenses alone increasing from 284 million RMB to 2.842 billion RMB during the same period [27]. - Despite maintaining a high gross margin of around 73%, the net profit margin has plummeted from 33.56% in 2018 to approximately 9.27% in 2024, indicating severe profitability issues [27][28]. - The company's strategy to cut costs and improve profitability through internal reforms may provide short-term relief, but long-term success will depend on genuine operational improvements [29][30].

Investment Rating - The report maintains an "Outperform" rating for the company [1][2][7] Core Views - The company achieved steady growth in 2024, with revenue of Rmb 3.03 billion (+5.5%) and net profit of Rmb 1.96 billion (+5.3%), maintaining a gross profit margin of 94.6% [3][11] - The company is focusing on overseas mergers and acquisitions, particularly the proposed acquisition of REGEN in South Korea, which is expected to significantly contribute to revenue and profits in 2026 [4][16] Financial Performance - Revenue and profit growth for 2024: Revenue of Rmb 3,026 million, net profit of Rmb 1,958 million, with a gross profit margin of 94.6% [3][11] - Q4 2024 performance showed a revenue decline of 7.0% to Rmb 650 million and a net profit decline of 15.5% to Rmb 370 million [12] - Revenue by product category: Solution-based products Rmb 1.74 billion (+4.4%), Gel-based products Rmb 1.22 billion (+5.0%), Facial implant threads Rmb 6.804 million (+15.0%), Other revenue Rmb 59.192 million (+68.5%) [13][14] Research and Development - Increased R&D investment with a ratio of 10.0% in 2024, focusing on new product pipelines and clinical trials [4][15] - The company has received clinical trial approvals for several new products, indicating a commitment to innovation [15] Acquisition Strategy - The proposed acquisition of REGEN for US$190 million is expected to enhance the company's product offerings and production capacity, with the second factory in South Korea expected to start production in Q2 2025 [4][16] - The target company reported revenue of Rmb 72.23 million and net profit of Rmb 29.5 million from January to September 2024 [16] Earnings Forecast and Valuation - Revenue projections for 2025 and 2026 are Rmb 3.30 billion and Rmb 3.60 billion, respectively, with year-on-year growth of 9.2% and 9.1% [5][17] - The target price is set at Rmb 299.47 per share, corresponding to a P/E ratio of 45x for 2025 and 42x for 2026 [7][17]

Core Viewpoint - Tmall's 2025 strategy emphasizes supporting high-quality, original brands rather than spreading resources evenly across all brands, indicating a shift towards fostering innovation and creativity in the brand ecosystem [1][5][12]. Group 1: Strategy Implementation - The new strategy was not abruptly introduced but was piloted in the fast-moving consumer goods, apparel, and sports outdoor sectors for several months, showcasing data results to brand partners before a broader rollout [4]. - Tmall's support for original brands includes extending the incubation period for new products from 30 days to 90 days and doubling the number of supported new products from 4,000 to 8,000 [14][19]. Group 2: Current Brand Ecosystem - The current brand ecosystem is characterized by a decline in innovation, with a 3% decrease in new cosmetic product registrations in 2024 compared to 2023, and a 14.6% drop in new products from major international cosmetic brands in China [7]. - Many mature brands have relied on retail channel efficiency rather than product innovation, leading to a decline in their competitive edge and market share [8][9]. Group 3: Tmall's Competitive Advantage - Tmall's strategy aims to leverage its high repurchase rates and user engagement, with 90-day repurchase rates averaging 15% across industries and 30% for member users [18]. - The platform's focus on expanding user purchase categories and enhancing member benefits is designed to create a closed-loop system that maximizes value for both Tmall and brands [19]. Group 4: Market Trends and Future Outlook - The trend towards supporting original brands is expected to create significant growth opportunities, with 469 emerging brands achieving top sales in niche categories during the 2024 Double 11 shopping festival [26]. - Tmall's commitment to fostering original brands is anticipated to lead to the emergence of innovative brands capable of creating new market segments [27].

Core Insights - The skincare market for international brands like Estée Lauder and L'Oréal is facing challenges, prompting a shift towards the medical aesthetics sector [1][4] - Estée Lauder has partnered with Jiahui Medical to establish a clinical research center focused on post-surgical skincare solutions [1][5] - The beauty industry is witnessing a trend towards "medical beauty," with brands integrating effective skincare products with medical aesthetics [4][6] Group 1: Company Strategies - Estée Lauder's brands, including La Mer and Clinique, are launching medical device products aimed at post-surgical recovery, indicating a strategic pivot towards medical aesthetics [1][5] - L'Oréal has been proactive in the medical aesthetics space, introducing products like the "Platinum Research" collagen injection and investing in high-end medical chains [6][7] - Amorepacific has also entered the market with its high-end brand "AP," focusing on post-surgical skincare products priced between 2000-3000 RMB [5][6] Group 2: Market Dynamics - The high-end skincare market is experiencing a significant decline, with Estée Lauder reporting an 8% drop in skincare sales in Q3 2024 and a further 12% in Q4 2024, leading to a total revenue loss of $300 million [4] - Competitors like Beiersdorf are also struggling, with its luxury brand La Prairie seeing a 15% sales decline in 2023 and a 6% drop in 2024 [4] - The domestic medical aesthetics market is becoming increasingly competitive, with companies like Aimeike facing growth slowdowns despite a 5.45% revenue increase in 2024 [9][10] Group 3: Future Outlook - Aimeike's acquisition of an 85% stake in Korean company REGEN for approximately 1.4 billion RMB highlights the need for companies to strengthen their technological capabilities in the face of rising competition [11] - The competition between international beauty brands and domestic medical aesthetics firms is intensifying, focusing on brand strength and clinical validation versus technological barriers and channel control [11]

Core Insights - The domestic market is on the verge of launching its first PDRN product, with Jiangsu Wuzhong completing clinical trials and planning to submit for market approval in the second half of the year [1][2][3] - PDRN, known as "salmon needle" in the aesthetic medicine market, has gained significant attention due to its ability to stimulate collagen and elastin production, making it valuable for skin repair and anti-aging [3][5] - The global PDRN market is projected to grow fivefold in the next five years, reaching $285 million by 2029, with China expected to have the highest growth rate at a compound annual growth rate (CAGR) of 49.02% from 2023 to 2029 [9][10] Industry Dynamics - Over 20 domestic companies are currently involved in the PDRN sector, including major players like Huaxi Biology and Jiangsu Wuzhong, indicating a competitive landscape [3][5] - The initial applications of PDRN were in wound healing and tissue regeneration, but its efficacy in anti-aging has led to a shift towards aesthetic applications [5][6] - The entry of domestic companies into the PDRN market has been accelerated by significant investments and acquisitions, highlighting the commercial potential of PDRN products [6][19] Market Competition - The current market is dominated by imported PDRN products, primarily from South Korea, which poses a challenge for domestic brands to establish themselves [10][12] - The success of Korean brands in China has been attributed to tailored product offerings and effective marketing strategies, including partnerships with beauty institutions [15][19] - Domestic PDRN products have the opportunity to capture market share by focusing on compliance and quality, as existing products lack regulatory approval [18][19] Future Outlook - The first approved PDRN product is expected to create a significant market opportunity, potentially becoming a blockbuster in the aesthetic medicine sector [18][19] - The competition among aesthetic products, including PDRN, PLLA, and PCL-based injections, will intensify as companies innovate and seek to differentiate their offerings [21][23] - The strategic focus on product compliance, market education, and efficient distribution will be crucial for domestic companies to succeed in the evolving landscape of aesthetic medicine [19][23]

一直以来，中免集团始终坚守对产品和服务品质的严格把控。从采购端到零售端，中免集团精细化 运营管理，确保每一件商品都能成为品牌良好形象的有力载体。中免集团矢志不渝做品牌商开拓中国市 场最值得信赖的合作伙伴，成为国潮出海最可信赖的通道，助力更多优秀的中国品牌迈向国际舞台。 未来，中免集团将继续积极助力国潮品牌的国际化进程，通过海外渠道拓展、文化融合创新等方 式，推动国潮品牌走向世界，携手全球伙伴共同书写旅游零售行业高质量发展的新篇章。 会上进行了国潮出海及战略品牌签约活动，中免集团与华熙生物科技股份有限公司、巨子生物集 团、上海自然堂集团有限公司、依文控股有限公司、仙游三鼎文化艺术有限公司、莆田藏云堂艺术品有 限公司、青春之家（福建）体育用品有限公司以及厦门天行客数字科技有限公司等8家极具代表性的国 潮品牌签署了战略合作协议。 此次战略合作签约是中免集团持续深化与国潮品牌合作的重要里程碑。中免集团作为全球领先的旅 游零售商，将充分发挥自身在全球渠道网络、供应链管理和消费者洞察方面的优势，为国潮品牌提供从 产品推广到渠道拓展的全面支持。这些国潮品牌也将在深度合作的基础上加速海外市场布局，推动中国 文化与全球消费的深 ...